Reviva Pharmaceuticals Holdings Inc. has announced the publication of new clinical vocal biomarker data from the RECOVER Phase 3 clinical trial evaluating brilaroxazine for the treatment of negative symptoms in schizophrenia. The findings, published in the peer-reviewed journal Biological Psychiatry, indicate that speech latency can serve as an objective biomarker to assess treatment response and may help reduce sample sizes and enhance outcomes in clinical trials for schizophrenia. The results reinforce brilaroxazine’s therapeutic effect on negative symptoms and other symptom domains and support its efficacy as assessed by clinicians. The publication is currently available, and the company highlights the potential of this approach to improve patient stratification and mitigate placebo responses in future schizophrenia clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reviva Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622009) on January 08, 2026, and is solely responsible for the information contained therein.